How does signalling via PI3K-PKB (AKT)-mTORC1-p70S6K and ERK-p90RSK mediate wide-ranging physiological responses to insulin? Quantitative proteomics and biochemical experiments are revealing that these signalling pathways induce the phosphorylation of large and overlapping sets of proteins, which are then captured by phosphoprotein-binding proteins named 14-3-3 s. The 14-3-3 s are dimers that dock onto dualphosphorylated sites in a configuration with special signalling and mechanical properties. They interact with the Rab GTPase-activating proteins AS160 and TBC1D1 to regulate glucose uptake into target tissues in response to insulin and energy stress. Dynamic patterns in the 14-3-3-binding phosphoproteome are providing new insights into how insulin triggers coherent shifts in metabolism that are integrated with other cellular response systems.
Established and emerging actions of insulin
Insulin is best known for suppressing blood glucose levels by driving glucose from the bloodstream into muscle and liver glycogen and into fat in adipose tissue, and for inhibiting glucose production from the liver. However, these actions are only part of an orchestrated shift in global metabolism induced by insulin action. Nutrients and ions surge into our bloodstream after a meal, and insulin directs the assimilation of glucose, metal ions, amino acids and lipids according to the demands of specialized tissues in ways that ensure whole-body homeostasis, electrochemical balance of ions across membranes, and stoichiometric balance in fluxes through metabolic pathways.
Although the main targets for insulin-regulated glucose homeostasis are muscle, fat and liver, insulin also prepares other organs in their response to food. For example, it was recently discovered that insulin induces cytoskeletal remodelling in kidney glomerular podocytes [1] and thus readies the kidney for increased urine filtration following a meal. Insulin influences vascular endothelium in ways that may affect tissue blood flow, and regulates fuel use and cell survival in the heart [2] [3] [4] [5] . Insulin signalling to the hypothalamus, pituitary, bone, pancreas and reproductive systems is also being recognised as critical to the whole-body distribution of resources [6] [7] [8] [9] .
The discovery that insulin has more widespread influences than was previously realised implies that complications of diabetes such as neuropathies, nephropathy, bone disorders and heart disease might not be solely attributable to hyperglycaemia, but could be due in part to deregulated insulin action in the damaged tissues [10] . In any case, an understanding of how insulin exerts its diverse effects on different tissues is of enormous practical significance given the growing worldwide burden of insulin resistance and type 2 diabetes.
The immediate effects of insulin binding to its cognate tyrosine kinase receptor are relatively well understood. Phosphatidyinositol 3-kinase (PI3K)-protein kinase B (PKB, also known as AKT)-mammalian target of rapamycin complex 1 (mTORC1)-p70 ribosomal S6 kinase (p70S6K) signalling is activated, and in some cell types insulin also activates the Ras-Raf-extracellular signalregulated kinase (ERK)-p90 ribosomal S6 kinase (p90RSK) pathway [11, 12] . However, too few downstream targets are known to explain how these core signalling pathways stimulate diverse physiological responses to insulin. Here, we review the roles of a family of phosphoprotein-binding proteins named 14-3-3 s in mediating insulin responses. We outline how 14-3-3 proteins work and focus on contributions of 14-3-3 s to key regulatory steps in insulin-regulated glucose homeostasis. Recent developments in 14-3-3 affinity capture and proteomics technologies are also highlighted, which show promise as a way to identify new intracellular targets and help to explain the wider actions of insulin.
14-3-3 dimers dock onto specific pairs of phosphorylated sites The 14-3-3 s dock onto and regulate hundreds of phosphoproteins inside eukaryotic cells, including proteins that are deregulated in diabetes, cancer and neurological disorders ( Figure 1 ). Mammals have seven 14-3-3 genes (gamma, epsilon, beta, zeta, sigma, theta, tau), and their peculiar name refers to the discovery of the protein isoforms as a cluster of spots in position 14-3-3 on an early two-dimensional starch gel separation of bovine brain extract (Box 1) [13] . The numbers 14-3-3 have no functional significance; perhaps a more meaningful number for these proteins is 'two', for they are dimers that bind two phosphorylated residues. Often a 14-3-3 dimer docks onto a pair of tandem phosphorylated sites on a target protein, which is a configuration that confers interesting signalling and mechanical properties [14] [15] [16] .
The act of docking onto two phosphorylated residues turns a 14-3-3 dimer into a type of biochemical microcontroller called a logic gate (Figure 2a ). Logic gates are fundamental components of digital electronic circuits, where they perform OR and AND operations on two or more inputs to produce a single output. The concept is useful because an increasing number of proteins are being identified in which two tandem phosphorylated 14-3-3-binding sites can be phosphorylated by distinct protein kinases [15] . One is the BCL-XL/BCL2-associated death promoter (BAD) for which the 14-3-3 has been proposed as an OR gate because phosphorylation of either site is sufficient to recruit 14-3-3, which in turn promotes cell survival by preventing BAD binding to the anti-apoptotic BCL-XL [17] . The 14-3-3 would be an AND gate if both sites must be phosphorylated, and by different kinases, for a 14-3-3 to bind and exert its action. Such devices would filter out signalling noise because only the correct combination of inputs would trigger an output. In biological systems, the digital logic is likely to be more 'fuzzy' than in electronic circuits, because the phosphorylation and binding kinetics often differ for the two 14-3-3 interaction sites. Later in this Figure 1 . The current 14-3-3 diseasome encompasses tumourigenesis, cardiovascular, metabolic and neurological disorders. Some 480 human disease gene sets described in the Genetic Association Database were recently mapped to indicate the degree of gene sharing among diseases [68] . We extracted from this disease map the gold standard proteins with defined 14-3-3-binding phosphorylation sites [15, 69] . The 14-3-3 binders map predominantly in four disease classes: tumourigenesis (11 proteins: P53, BRAF, MDM2, CDN1B, AKP13, IRS1, PRLR, CTNB1, CHK1, ABL1, GLI2), cardiovascular (6 proteins: GP1BA, TY3H, ITB2, MEFV, IRS1, CDN1B), metabolic (5 proteins: IRS1, GP1BA, TY3H, IGF1R, MEFV) and psychiatric or behaviour (11 proteins: TAU, IGF1R, GP1BA, P53, LRRK2, TY3H, ACHA4, MEFV, COF1, SLIK1, TPH2). The protein overlap between these classes is illustrated here by Visant graphing (http://visant.bu.edu). This map is just a starting point, with indications that the concentration of 14-3-3-binding proteins in the tumourigenesis, cardiovascular, metabolic and neurological disease classes will increase. For example, AS160 and TBC1D1, mutations of which are found in subtypes of diabetes and obesity, respectively [56, 61, 62] , were not in the Genetic Association Database when the disease map was prepared [68] . Moreover, further proteins linked to these four disease classes are among those that exhibit affinity for 14-3-3 s in high-throughput proteomics studies; these await biochemical studies to define the specificity of their interactions with 14-3-3 [23, 24, 26, 27] .
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In electronic circuits, the output of a logic gate is an electrical impulse. In intracellular circuits, a 14-3-3 docking event triggers a mechanical action [18] . The two phosphorylated 14-3-3-binding sites on target proteins are generally located within disordered regions and/or straddle a functional domain [15] . Their positions can give clues about how 14-3-3 dimers modulate the conformations and interactions of their targets (Figure 2b ). 14-3-3 s can act as levers, whereby one site acts as a fulcrum for the 14-3-3 dimer to exert a force on the other site, which causes a conformational change in the target. For example, a 14-3-3 dimer alters the conformations of phosphorylated tyrosine hydroxylase and the GTPase-activating protein RGS3 to activate these enzymes [19, 20] . In other cases, 14-3-3 dimers mask a subcellular targeting sequence or a functional domain. For example 14-3-3 binds to PKB-phosphorylated FOXO4, which shields the DNA binding interface of this transcription factor and also interferes with its nuclear localization [21] . In this way, 14-3-3 inhibits transcriptional activation when FOXO4 is phosphorylated in response to insulin and other stimuli. In principle, a 14-3-3 dimer could clip back flanking regions to better present a functional domain for external interactions, but there are 14-3-3 dimers are logic gates and mechanical devices that dock onto two CAMK-and AGC-phosphorylated sites. (a) Analogy between a 14-3-3 dimer and digital logic gates. Digital AND and OR gates, which integrate two inputs into a single output, are depicted on the right. The left-hand side shows how the act of docking onto two sites, which may be phosphorylated by different kinases, turns the 14-3-3 dimer into a digital logic gate whose output is a mechanical action. (b) The 14-3-3 s are dimeric regulatory proteins that dock onto two phosphorylated residues, which are usually on the same target protein. Mechanically, this means that 14-3-3 can act as levers to force a conformational change in a target, can mask a functional domain within the central groove, and can potentially clip back flanking regions to present a functional domain for external interactions. When the two phosphorylated 14-3-3-binding sites are on different proteins, the 14-3-3 dimer would be an adapter that stabilises the interaction between the two targets. 14-3-3 s are remarkable for having hundreds of phosphoprotein partners. (c) Phosphorylated 14-3-3-binding sites are created by CAMK and AGC kinases. The frequency plot at the bottom was generated by aligning the sequences around more than 200 14-3-3-binding sites, centred on the phosphorylated 14-3-3-binding residue, which can be serine or threonine [15] . Most 14-3-3-binding sites have arginine somewhere in the -3 to -5 positions relative to the phosphorylated site, and just under half have a proline at +2. Such sites are generally phosphorylated by basophilic kinases in the AGC and CAMK sections of the human kinome, including central mediators of insulin and nutrient signaling.
Trends in Endocrinology and Metabolism November 2011, Vol. 22, No. 11 no compelling examples of this. A 14-3-3 dimer may also act as an adapter linking two phosphorylated proteins, and a convincing case of this mode of action is the stabilisation and activation of the hexomeric plasma membrane proton ATPase in plants by phosphorylation-dependent interactions with three 14-3-3 dimers [22] .
AGC and CAMK protein kinases phosphorylate many 14-3-3-binding sites 14-3-3 s interact with many phosphoproteins [23] and provide a common mechanism for linking signalling pathways to cell metabolism, growth, proliferation and morphology. With so many targets and over 500 human protein kinases, it seems daunting to sort out which kinase phosphorylates which 14-3-3-binding sites and when. Fortunately, the task is simplified because much of the kinome can be disregarded: 14-3-3 s do not bind to phosphorylated tyrosines, nor generally to phosphorylated serines and threonines that are followed by proline residues. This means that neither tyrosine kinases nor proline-directed enzymes, such as mitogen-activated protein (MAP) kinases and cyclin-dependent protein kinases, create docking sites for 14-3-3 s. Mode I RXX(pS/pT)XP and mode II RX(F/Y)X(pS)XP sequence motifs showed optimal binding to 14-3-3 s in a screen of a phosphopeptide library [16] . In a recent survey of defined 14-3-3-binding sites in mammalian proteins, mode I RXX(pS/pT)XP motifs dominate, although the +2 proline residue occurs in less than half (Figure 2c) . Interestingly, these 14-3-3-binding sequences overlap with the specificities of the protein kinase A/protein kinase G/protein kinase C (AGC) group and Ca 2+ /calmodulin protein kinase (CAMK) group of protein kinases [15] , which exhibit individual preferences for phosphorylating motifs with basic residues in the -3 to -5 positions relative to the phosphorylated residue. These basophilic kinases include proviral integration of MMLV (PIM) kinases, protein kinase C (PKC) isoforms, the energy-sensing AMP-activated protein kinase (AMPK), and the insulin-activated PKB, SGK, p70S6K and p90RSKs (Figure 2c ).
14-3-3 capture and release combined with differential proteomics There are many proteins whose binding to 14-3-3 s is dynamically regulated by insulin, growth factors and nutrients. Their identification is aided by recent developments in high-resolution mass spectrometry and quantitative proteomics; thus, proteins within complex mixtures can be identified and quantified, and their post-translational modification status can be analysed. For example, 14-3-3 affinity capture can be used to isolate 14-3-3-binding proteins from lysates of two or three sets of cells exposed to different agonists and/or inhibitors. Proteins that bind specifically to the immobilised 14-3-3 s can be released by competitive elution with a synthetic 14-3-3-binding phosphopeptide. After digestion of the proteins, the peptides are reacted with formaldehyde and borohydride to dimethylate every primary amine, with the chemicals for each preparation labelled with different stable isotopes to generate a 'light', 'intermediate' or 'heavy' dimethyl moiety. Mass spectrometry is then used to identify the sequence of the peptides, and to determine the ratio of the light, intermediate and heavy forms of each peptide. In this way, proteins whose peptides are more abundant in, for example, the 14-3-3-captured sample from insulin-stimulated than from unstimulated cells or inhibitor-treated cells can be identified [24, 25] . Because the dimethyl labelling step is carried out after proteins are proteolytically digested, this method has potential to identify insulin-regulated proteins isolated from their physiological target tissues. Another strategy uses a similar principle, except that the differential isotope label is introduced into proteins by metabolic incorporation of 'light', 'intermediate' or 'heavy' stable isotopically labelled amino acids that are fed to cells in culture (SILAC) [26, 27] . Other quantitation methods, such as differential isobaric tag for relative and absolute quantitation (iTRAQ) labelling of protein and peptide samples and even label-free methods, are also possible, and each method has its advantages and disadvantages [27, 28] .
14-3-3 phosphoproteomics data indicate new regulatory mechanisms for insulin
The first experiments using 14-3-3-phosphoproteomics technology have identified many proteins that bind to 14-3-3 s in response to signalling pathways that are activated by insulin [24, 26, 27] . The insulin-regulated 14-3-3-binding sites have been verified for fewer proteins. Some of these proteins have poorly defined functions, including coiled-coil domain protein 6 (CCDC6), the E3 ubiquitin ligase zinc-finger, RING-finger 2 (ZNRF2), and the sterile alpha motif (SAM) and SRC homology 3 (SH3) domain protein SASH1 [24] . Intriguingly, it was found that a single-nucleotide polymorphism in the SASH1 gene is associated with diabetic nephropathy genes in African Americans in a genome-wide study, so study of this protein may reveal new disease mechanisms [10] . Other insulinregulated 14-3-3-binding proteins provide more immediate insights into the known actions of the hormone. These include proteins that regulate insulin-stimulated glucose uptake into tissues, namely the Rab GTPase-activating proteins AS160 (TBC1D4) and TBC1D1; the myosin MYO1C; the cardiac glycolytic activator PFKFB2; the transcriptional regulator and E3 SUMO-protein ligase PIAS2 (Miz1); transcription factors FOXO1, FOXO3, FOXO4 and capicua; ECD3, which is involved in decapping mRNA as a step in its degradation; cell cycle and apoptotic Box 1. 14-3-3 proteins 14-3-3 s are phosphoprotein-binding proteins with many regulatory roles in all eukaryotes. Dimers of curved L-shaped monomers (30 kDa) form a central groove that docks onto two phosphorylated sites on targets. AGC and CAMK kinases phosphorylate many of the known 14-3-3-binding sites. The two phosphorylated docking sites must be spatially compatible with fitting into either side of the central groove (35 Å across). Different eukaryotic lineages have evolved sets of 14-3-3 isoforms (e.g. gamma, epsilon, beta, zeta, sigma, theta and tau in mammals). All 14-3-3 isoforms share a similar mode of action, but may differ in their ability to form hetero-and homodimers, in affinities for different targets, in expression patterns and in their posttranslational regulation.
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Trends in Endocrinology and Metabolism November 2011, Vol. 22, No. 11 control proteins including CDKN1B (p27, Kip1), beta-catenin, BAD and BIM; and components of the insulin signalling PI3K-PKB-mTOR pathway itself, namely IRS2 (insulin receptor substrate 2), PRAS40 (AKT1S1) and rictor [3, 17, 21, 24, 26, 27, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Overall, a network of 14-3-3-phosphoprotein interactions is emerging that is providing mechanistic insights into how insulin stimulates glucose assimilation, activates cardiac glycolysis, and regulates transcription, protein synthesis, feedback control of insulin signalling, cytoskeletal dynamics and other intracellular events.
It should be emphasised that none of the above-mentioned proteins are regulated solely by insulin. Insulin signalling and other pathways converge on several 14-3-3-binding sites, and some of these proteins are also modulated by energy and nutrient levels [41] . An intriguing idea is that 14-3-3 dimers as fuzzy AND logic gates might integrate insulin signals with other inputs. For example, there is an interplay between insulin and amino acids in stimulating phosphorylation of the 14-3-3-binding site(s) on PRAS40 [42, 43] . In addition, 14-3-3 interacts with the cardiac PFKFB2 via a high-affinity PKB-phosphorylated site and a second site that can be phosphorylated by both PKB and AMPK, which is activated when the energy or ATP status of cells is low, for example during ischaemia [3, 44] . Insulin enhances the ability of cardiomyocytes to survive ischaemia, and a functional role for 14-3-3 is indicated by the finding that the PKB-mediated increases in fructose-2-6-bisphosphate levels and glycolysis are prevented by a cell-permeable 14-3-3-binding phosphopeptide in cells containing cardiac PFKFB2 [3] .
Another key physiological process in which insulin signalling is integrated with other inputs is the uptake of glucose into muscles [45] . The goal of improving glucose control in individuals means that the underlying mechanisms are under intense research, and the next section outlines the contributions of two 14-3-3-binding proteins, the related Rab GTPase activating proteins (Rab-GAPs) AS160 (TBC1D4) and TBC1D1. Both proteins are regulated by multiple phosphorylations [46, 47] and details of relevant kinases and the roles of some sites are still controversial, a situation that is being resolved with improved reagents for phosphosite identification and quantification. Readers should therefore note that we do not attempt to be comprehensive here, but present a personal 14-3-3-centred perspective with a testable hypothesis.
Differential regulation of AS160 and TBC1D1
Insulin promotes glucose uptake into muscles and fat through GLUT4 glucose transporters [48] . In unstimulated cells, GLUT4 is localised to internal storage vesicles that must fuse with the plasma membrane before glucose can flow into cells. GLUT4 trafficking to the plasma membrane is stimulated by insulin signalling mainly via the PI3K-PKB pathway, and impairment of this process is an early sign of insulin resistance and type 2 diabetes [46, 48] . In skeletal and cardiac muscle, GLUT4 trafficking is also activated by contraction, which activates protein kinases, including AMPK, which is activated by lowering ATP levels [49] . There is considerable interest in understanding how exercise, as well as drugs that activate AMPK, restore glucose homeostasis in individuals with insulin resistance [50] .
GLUT4 trafficking requires active GTP-bound Rab proteins. AS160 and the closely related Rab-GAP, TBC1D1, promote GTP hydrolysis by Rabs. It has been proposed that these Rab-GAPs are somehow inactivated by phosphorylation via insulin and AMPK signalling, which allows the relevant Rabs to be loaded with GTP to facilitate GLUT4 trafficking [51] [52] [53] [54] . AS160 and TBC1D1 have similar domain architectures, and both proteins have two 14-3-3-binding sites that are located within clusters of multisite phosphorylation in a part of the protein that also has socalled PTB domains (Figure 3 ). Beyond this superficial similarity, however, some key regulatory details for AS160 and TBC1D1 are distinct.
AS160 is named for its discovery as an AKT (PKB) substrate, and the effects of overexpression of a nonphosphorylatable mutant [AS160(4P)] first implicated this protein in GLUT4 trafficking [53, 55] . Furthermore, a recent genetic analysis identified patients with severe insulin resistance during puberty who carry a premature stop mutation in one allele of AS160 [56] , which underscores the need to define precisely how AS160 regulates glucose homeostasis. Insulin stimulates phosphorylation of several sites of AS160 and induces its binding to 14-3-3 s mainly through PKB-phosphorylated Thr642, with support from phospho-Ser341, which can be phosphorylated by p90RSK and PKB [29, 37, 53] . A form of AS160 that binds 14-3-3 constitutively, generated by genetic mutation, could override the inhibitory effect of AS160(4P) on GLUT4 translocation in adipocytes [29, 37, 53] . In addition, insulinstimulated fusion of GLUT4 vesicles with the plasma membrane was prevented by blocking the AS160-14-3-3 interaction in cell-free assays, which further indicates a functional role for 14-3-3 in this process [57] . It was initially proposed that Thr642 on AS160 was a convergence point for phosphorylation by both PKB and AMPK [58] . However, in vitro and cell culture studies suggest that whereas AMPK may phosphorylate other residues, AMPK does not seem to be a physiological Thr642 kinase [29, 59] . Therefore, 14-3-3 binds to phospho-Thr642 and phosphoSer341 in response to insulin and growth factors, and not AMPK activators (Figure 3) .
In contrast to AS160, AMPK has a clear role in mediating 14-3-3 binding to the related TBC1D1 [60] . TBC1D1 was originally identified as a candidate gene underlying severe familial female obesity [61] and its natural deletion in mice resulted in leanness and protection against dietinduced obesity [62] . TBC1D1 and AS160 share a similar substrate preference towards Rabs, at least in vitro [63] , and overexpression of a form of TBC1D1 mutated at three of its phosphorylation sites interfered with GLUT4 translocation in 3T3-L1 adipocytes [64] .
In cultured L6 myotubes and intact skeletal muscles, whereas AS160 is phosphorylated on Ser341 and Thr642 and binds to 14-3-3 s in response to insulin, TBC1D1 is phosphorylated on Ser237 and binds to 14-3-3 s in response to acute exercise [65] and pharmacological AMPK activators [60, 66] . Insulin and growth factors also stimulate the phosphorylation of a second 14-3-3-binding site at Thr596 of TBC1D1, which is similar to Thr642 of AS160; thus, TBC1D1 seems to be a dual-input 14-3-3 logic gate ( Figure 3) . The functional significance of this molecular arrangement is not yet clear, however, and, at least in muscles, phosphorylation of Thr596 alone is insufficient for 14-3-3 binding [60, 65] .
Complementary roles of AS160 and TBC1D1 for insulin and AMPK activators We propose that 14-3-3 binding to AS160 regulates glucose homeostasis in response to insulin, whereas 14-3-3 binding to TBC1D1 regulates this process in response to AMPKactivating stimuli (Figure 3 ). To test this hypothesis of complementary roles for AS160-14-3-3 and TBC1D1-14-3-3 complexes in GLUT4 regulation, mice with knock-in mutations in the 14-3-3-binding phosphorylation sites in AS160 and TBC1D1 must be generated. Unlike studies using ectopic overexpression, introduction of a point mutation of a phospho-Ser/Thr residue to a nonphosphorylatable residue using knock-in genetic technology generally results in expression of mutant proteins at endogenous levels [67] (provided that mutations do not cause unexpected outcomes such as destabilisation of the protein), without exerting dominant-negative effects or competition from wild-type proteins.
First, a mouse model with Thr649 on AS160 (equivalent to Thr642 on human AS160) substituted by alanine was generated to prevent insulin-stimulated binding to 14-3-3 in vivo [67] . The most striking phenotype of the AS160-Thr649Ala knock-in mice is their altered glucose homeostasis, including glucose intolerance and reduced insulin sensitivity. Despite elevated total GLUT4 protein levels in skeletal muscles and fat tissues of the knock-ins, GLUT4 is not efficiently localised to the cell surface, which results in a reduced glucose uptake rate in muscle in response to insulin [67] . Together, these findings confirm that insulin-stimulated Thr649 phosphorylation and 14-3-3 binding to AS160 in muscle has a key role in glucose homeostasis.
Further experiments are needed to address the complexity of the glucose uptake process, including genetic tests of the roles of the AMPK and insulin-regulated 14-3-3-binding sites on TBC1D1. For wider health implications, we need to know if the knock-in mice display altered physiological responses to high-fat diets and ageing. Will the phenotype of TBC1D1 mice provide an insight into the obesity of individuals with mutations or polymorphisms in this protein or gene? Would genetic crosses between the knock-in AS160 and TBC1D1 mice and 'diabetes loci' reveal synergism with respect to insulin resistance? Answers to such questions would help to determine whether it would be useful to devise drugs that mimic the effects of insulin and exercise on AS160 and TBC1D1 as means to improving blood glucose management.
The future: 14-3-3-phosphoproteome barcodes More general lessons may also be learned from this narrow focus on AS160 and TBC1D1. Earlier in this review, we alluded to the possibility of using 14-3-3 capture and Figure 3 . Hypothesis of complementary regulation of glucose homeostasis by AS160 and TBC1D1 in skeletal muscles. Domains, motifs and disease-associated mutations (the latter in red) are shown in bar diagrams of AS160 and TBC1D1 (see the text for sources). PTB1 and PTB2 are phosphotyrosine interaction domains (by sequence, although their interaction partners have not been reported); CBD is a calcium-regulated region; and Rab GAP is the Rab GTPase-activating domain. In the hypothesis shown here, AMPK controls GLUT4 trafficking through Ser237 phosphorylation and consequent docking of 14-3-3 onto the TBC1D1 protein, whereas the insulin-PKB (AKT) pathway regulates surface translocation of GLUT4 via Thr642 phosphorylation and consequent 14-3-3 binding of the AS160 protein. This hypothesis does not take into account that both TBC1D1 and AS160 also receive other regulatory inputs via the other phosphorylations that are clustered close to the 14-3-3-binding sites on these proteins. Phosphorylated residues are indicated by numbers above the bar diagrams, with the 14-3-3-binding sites in yellow. R125W is an obesity-linked mutation of TBC1D1 [61] , and R363W is a diabetes-linked mutation of AS160 [56] .
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Trends in Endocrinology and Metabolism November 2011, Vol. 22, No. 11 phosphoproteomics to identify the commonalities and differences in insulin targets in specialised organs of the body. Another exciting issue would be the potential of developing these technologies to track which signalling pathways are activated in cells and tissues under normal conditions and in response to therapeutic drugs. As exemplified by the contrast between AS160 and TBC1D1, each protein has its own signalling signature, meaning its own pattern of responsiveness to one, two or many signalling pathways. In turn, this means that insulin, growth factors and other stimuli, which activate signalling pathways to different extents, will each induce the phosphorylation and 14-3-3 binding of distinct, but overlapping, subsets of targets. In other words, each stimulus will have its own 'barcode' within the 14-3-3 phosphoproteome in individual cells and tissues. Definition of the commonalities and differences in insulin responses in specialised organs and cells of the body, and any further overlaps between the insulinregulated 14-3-3 phosphoproteome and emerging genetic maps of diabetes and other diseases, will be important priorities for future metabolic research ( Figure 3 ).
